A vaccine expert breaks down everything you need to know about the Novavax vaccine.
With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
The mechanisms behind vaccine-related and pill-related clots are quite different.
How do we reasonably and accurately balance the risks of the AstraZeneca vaccine against the benefits? Conceptualising risk can be tricky, but the government's latest advice is sensible.
This shift in focus away from AstraZeneca to the Pfizer vaccine has serious impacts on the timing of the rollout and public confidence in the AstraZeneca vaccine.
The UK's proposal to give under-30s other vaccines shouldn't be too disruptive, but in Europe, greater restrictions look likely.
All vaccines and medications come with risks. But the risks of delaying vaccination are far higher.
Scientists have called it "vaccine-induced prothrombotic immune thrombocytopenia", or VIPIT. The condition is characterised by a shortage of platelets in the blood.
We need to stop relying on small GP clinics and urgently move towards using mass vaccination hubs like stadiums, schools and parks.
Exports of the vaccine continue to be a point of contention between the EU and UK, while newly released US trial results are quickly amended.
These results can help allay previous concerns in Europe about a lack of trial data for older people.
AstraZeneca just announced results from its US-based trial. It found the vaccine to be 79% effective and safe for use, despite recent concerns around reports of blood clots.
From today, around 1,000 clinics around the country can begin vaccinating eligible Australians.
The European Medicines Agency has said the Oxford/AstraZeneca vaccine is not associated with an increased overall risk of developing blood clots.
Suspensions of the AstraZeneca vaccine may dent confidence and will slow down coverage – arguably creating a greater risk to public health.
Injected vaccines tend to generate good immunity overall but less of a response in the nose and throat, where the virus enters and spreads from.
Data from clinical trials and the real world COVID vaccine rollout suggest blood clots occur no more frequently in vaccinated people than they do in the general population.
The European Medicines Agency has found no link between thrombosis and the AstraZeneca vaccine, but precautionary investigations are continuing in some countries.
With four COVID-19 vaccines approved for use in Canada, it's time to answer FAQs about efficacy, immunity, eradication and variants.
Fears that the vaccine doesn't work in older people appear unfounded.